目的 观察普拉洛芬联合氯替泼诺治疗白内障患者术后炎症的临床疗效。方法 选取2013年9月-2015年5月延安大学附属医院收治的白内障手术患者156例，随机分为对照组和治疗组，每组各78例。对照组在术后采用氯替泼诺混悬滴眼液治疗，治疗组在对照组的基础上采用普拉洛芬滴眼液治疗，给药方式均为术后一周内2滴/次，6次/d，一周后减为2滴/次，4次/d。两组均连续给药两周。比较术后第3、7、15、30天两组患者的炎症评分、眼压、黄斑中心凹视网膜厚度（CMT）以及不良反应情况。结果 术后第3、7、15天，两组的炎症评分均高于术前，同组治疗前后差异均有统计学意义（P<0.05）；治疗组术后第3、7、15、30天的炎症评分均显著低于同期对照组，两组比较差异具有统计学意义（P<0.05）。术后第7、15天，对照组的眼压均高于术前，同组治疗前后差异均有统计学意义（P<0.05）；治疗组术后第7、15天的眼压均显著低于同期对照组，两组比较差异具有统计学意义（P<0.05）。术后第7、15、30天，两组的CMT均显著高于术前，同组治疗前后差异均有统计学意义（P<0.05）；治疗组术后第7、15、30天的CMT均显著低于同期对照组，两组比较差异具有统计学意义（P<0.05）。治疗组和对照组的不良反应发生率分别为24.36%、44.87%，两组比较差异具有统计学意义（P<0.05）。结论 普拉洛芬联合氯替泼诺对白内障术后抗炎效果显著，且可以降低眼压的升高，改善黄斑中心凹视网膜厚度，安全性高，具有一定的临床推广应用价值。

Objective To observe the clinical efficacy of pranoprofen combined with loteprednol in treatment of post-operative inflammation for patients with cataract. Methods Patients (156 cases) with cataract surgery in Yanan University Affiliated Hospital from September 2013 to May 2015 were randomly divided into control and treatment groups. Each group had 78 cases. Patients in the control group were given Loteprednol Etabonate Ophthalmic Suspension after surgery, while patients in the treatment group were given Pranoprofen Eye Drops on the basis of the control group. The administration methods were 2 drops/time in the first week after surgery, six times daily. After 1 week, the dosage was reduced to 2 drops/time, four times daily. Inflammatory scores, intraocular pressure, central macular thickness, and adverse reactions in two groups on the third, 7^th, 15^th, and 30^th day after surgery were compared. Results On the third, 7^th, and 15^th day after surgery, inflammatory scores in two groups were higher than those before surgery, and there were differences between two groups (P<0.05). Inflammatory scores in the treatment group on the third, 7^th, 15^th, and 30^th day after surgery were lower than those in the control group in the same period with significant difference between two groups (P<0.05). On the 7^th and 15^th day after surgery, intraocular pressure in the control group was higher than that before surgery, and there were differences between two groups (P<0.05). Intraocular pressure in the treatment group on the third, 7^th, and 15^th after surgery was lower than those in the control group in the same period, with significant difference between two groups (P<0.05). On the 7^th and 15^th day after surgery, CMT in two groups were higher than those before surgery, and there were differences between two groups (P<0.05).CMT in the treatment group on the 7^th, 15^th, and 30^th after surgery was lower than those in the control group in the same period, and the difference was statistically significant between two groups (P<0.05). The adverse reaction rates in the treatment and control groups were 24.36% and 44.87%, respectively, and there were significant difference between two groups (P<0.05). Conclusions Pranoprofen combined with loteprednol has a significant clinical effect in treatment of post-operative inflammation for patients with cataract, can reduce the increase of intraocular pressure, and improve CMT with high security, which has a certain clinical application value.